ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

House Disallows NCI Recision

March 14, 1975

House Appropriations Boosts NIH By $1 Billion In Draft Budget That Cuts Other HHS Programs

September 30, 2011

Ethics Advisory Board to Consider Compensation Issue

September 7, 1979

CIDAC Bids Not Limited To Cancer Research Centers

January 17, 1975

DRCCA Staff Boom To 145, Still Growing, Still Looking for People

November 25, 1983

Guest Editorial: Thoughts on Overusing Radiation in Medicine And Redeeming that Whole Body Scan Coupon

March 1, 2013